Deerfield
Deerfield is an investment management firm established in 1994 that specializes in advancing healthcare through investment, information, and philanthropy. With over $8 billion in funds, Deerfield invests broadly in both public and private healthcare sectors, targeting a diverse range of companies from early-stage drug research to established healthcare services and medical device firms. The firm typically maintains equity or debt interests in more than 100 companies. It employs the Deerfield Institute, which conducts extensive research to provide objective market intelligence, engaging with thousands of professionals annually to address complex healthcare challenges. Additionally, a portion of the firm's profits is allocated to the Deerfield Foundation to support various philanthropic initiatives.
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.